AstraZeneca Pharma, a Bengaluru-based pharmaceutical company, saw a significant 48% increase in net profit to Rs 58.25 crore in the fourth quarter of fiscal year 2025. The company’s results were announced after market hours, leading to a 0.78% rise in share prices to Rs 7,980 apiece on the NSE. This positive financial performance reflects the company’s strong position in the market and its ability to deliver growth amidst industry challenges and competition. As a key player in the pharma sector, AstraZeneca continues to demonstrate its resilience and strategic approach to driving profitability and shareholder value.
Read more from business-standard.com
